Latest Equities News

Income Asset Management Group reported a robust FY2025 with significant revenue and client growth, alongside strategic cost reductions and a new product launch planned for FY26.

Income Asset Management Group reported a 22% revenue increase and a significant reduction in net loss for FY25, underpinned by strategic cost cuts, debt repayment, and governance enhancements. The Group also launched a new managed account product and announced key board changes.

The 2025 annual report for SPDR Core Equity ETFs confirms compliance with accounting standards and provides detailed unitholder data, underscoring the funds' robust governance and market position.

Energy Technologies Limited reported a $11 million net loss for FY2025, reflecting a strategic pivot and ongoing capital challenges. Despite a 37% revenue drop, management highlights operational resilience and plans to stabilise through capital management.

OM Holdings reported a slight revenue increase in the first half of 2025 but faced a loss due to falling ferrosilicon prices, while maintaining strong cash flow and preparing key asset sales.

OM Holdings reported a significant turnaround to a US$9.6 million loss in H1 2025 despite stable revenue, driven by weaker alloy prices and operational challenges. The company also announced a conditional sale of its 13% stake in the Tshipi Borwa Manganese Mine.

Hummgroup Limited reported a robust FY25 with cash profit soaring to $52.9 million, a significant reduction in costs, and a maintained historically low credit loss ratio. The group also completed a full repayment of its Perpetual Notes, signaling improved capital efficiency.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

RMA Global Ltd reported a 13% revenue increase to $21.1 million in FY25, driven by growth in the US and New Zealand, alongside steady Australian performance. The company also recorded its first full-year positive operating cash flow, marking a significant financial turnaround.

Future Generation Global Limited has reported a 20.8% increase in its investment portfolio over the past year, prompting a boost in its fully franked interim dividend to 4.0 cents per share. This performance outpaces global market averages and underscores the company's sustainable investment approach.

Future Generation Global Limited reported a notable decline in half-year profits but raised its fully franked interim dividend, underscoring confidence in its investment strategy and ongoing commitment to youth mental health initiatives.